1. Type 1 diabetes of at least one year duration;

2. Treated with CSII therapy for at least 6 months;

3. Age 18 to 70 years, inclusive;

4. A1C >7.0 and ≤10% as screening;

5. BMI ≤35 kg/m2;

6. Stable insulin dose (±10%) for at least 3 months prior to screening;

7. If female, has a negative urine pregnancy test at screening;

8. If female and of childbearing potential, practicing and willing to continue to using appropriate contraception to ensure that pregnancy does not occur during the study;

9. Able to understand and sign the required study documents and comply with the protocol requirements

1. Is poorly compliant with the currently prescribed insulin regimen, as determined by the investigator;

2. Has any significant medical condition, laboratory findings, or medical history that may affect successful completion of the study and/or personal well-being;

3. If female and if of childbearing potential, is pregnant, lactating, or planning to become pregnant;

4. Has experienced recurrent severe hypoglycemia requiring assistance during the past 6 months;

5. Has a history of hypoglycemia unawareness;

6. Has a confirmed diagnosis of gastroparesis;

7. Requires the use of drugs that stimulate gastrointestinal motility;

8. Is receiving medications known to interfere with glycemic control (i.e. glucocorticoids);

9. Has been treated with any oral antidiabetic agent or exenatide within 3 months of screening visit;

10. Has been treated with pramlintide within 3 months of screening visit;

11. Has received an investigational drug within 3 month of screening visit;

12. Is currently participating in a clinical trial